|
Point-of-care testing for renal failure and chest pain - Pulse+IT Magazine - Pulse+IT Magazine |
 |
 |
|
Flinders University researchers are planning to run a study in six remote health centres in the Northern Territory to determine the patient benefits and cost savings of using point-of-care testing (POCT) devices.
The International Centre for Point-of-Care Testing at Flinders University will undertake the research following a $95,000 grant from the Emergency Medicine Foundation.
The centre currently runs Quality Assurance for Aboriginal and Torres Strait Islander Medical Services (QAAMS), a national service funded by the federal government that provides POCT for diabetes management and treatment at more than 170 Aboriginal and Torres Strait Islander medical services.
It also runs a program in association with the NT Department of Health using the Abbott i-STAT portable blood analyser.
It now intends to specifically investigate the use of POCT for patients with acute chest pain, acute diarrhoea and acute renal failure.
Centre director Mark Shephard said the research has the potential to lead to more services in rural and remote communities, which could lead to major health benefits as well as create substantial savings for the health system.
Professor Shephard said access to portable pathology testing means that doctors are able to rule out potential acute problems, stabilise patients in their own communities or confirm when emergency evacuations were required.
“In simple terms, this research will determine whether POCT enables more people to be diagnosed and treated in their remote communities, and whether it reduces the need for unnecessary and expensive medical retrievals,” he said.
“Hundreds of rural and remote Australians are medically evacuated to city hospitals each year at a significant cost to the health system.”
In addition to research into POCT in rural and remote areas, the centre also has expertise in device selection, analysis of evidence-based outcomes for POCT and the development of software solutions for the electronic capture of POCT results.
Would you like to receive articles like this one delivered straight to your email inbox each week?
Currently Pulse+IT eNewsletter subscribers are keeping up to date with the latest Australasian eHealth and Health IT developments using this free service. Click here to join now!
|
|
Work on new dialysis center in Wallingford continues - Meriden Record-Journal |
|
|
|
WALLINGFORD — Most of the space in a new North Main Street Extension building will be used by Wallingford Dialysis Care.
The business, owned by the Massachusetts-based American Renal Association, received approval from the Planning and Zoning Commission to change the use of the Corner Place building, 720 N. Main St. Extension, from office space to outpatient medical treatment.
Interior construction is underway. The business will use 7,500 square feet, leaving 2,500 square feet available. The business signed a 10-year lease with Verna Properties.
The dialysis center expects a maximum of 40 to 44 patients a day with no more than 20 cars using the parking lot at one time, according to Town Planner Kacie Costello.
Costello and Verna did not return a call for comment last week.
Corner Place was built in 2014 by an affiliate of Verna Properties and is located across from Community Pool and at the corner of Beaumont Road and North Main Street Extension.
The Proto Group, based out of North Haven, is looking for a tenant for the remaining space.
“Our first choice is to have a medical use in the building,” said Lou Proto, principal of the Proto Group,
“We’re open to any retail use, but we would prefer medical use.”
Economic Development Specialist Tim Ryan said he doesn’t think it will be difficult to find another tenant.
“When you have that combination: a good location, a brand new building and reputable landlords,” Ryan said, “you’ll find the right business.”
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
(203) 317-2235 Twitter: @EricVoRJ
|
|
|
Work on new dialysis center in Wallingford continues | MyRecordJournal.com | - Meriden Record-Journal |
|
|
|
WALLINGFORD — Most of the space in a new North Main Street Extension building will be used by Wallingford Dialysis Care.
The business, owned by the Massachusetts-based American Renal Association, received approval from the Planning and Zoning Commission to change the use of the Corner Place building, 720 N. Main St. Extension, from office space to outpatient medical treatment.
Interior construction is underway. The business will use 7,500 square feet, leaving 2,500 square feet available. The business signed a 10-year lease with Verna Properties.
The dialysis center expects a maximum of 40 to 44 patients a day with no more than 20 cars using the parking lot at one time, according to Town Planner Kacie Costello.
Costello and Verna did not return a call for comment last week.
Corner Place was built in 2014 by an affiliate of Verna Properties and is located across from Community Pool and at the corner of Beaumont Road and North Main Street Extension.
The Proto Group, based out of North Haven, is looking for a tenant for the remaining space.
“Our first choice is to have a medical use in the building,” said Lou Proto, principal of the Proto Group,
“We’re open to any retail use, but we would prefer medical use.”
Economic Development Specialist Tim Ryan said he doesn’t think it will be difficult to find another tenant.
“When you that combination: a good location, a brand new building and reputable landlords,” Ryan said, “you’ll find the right business.”
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
(203) 317-2235 Twitter: @EricVoRJ
|
|
Company Shares of Rockwell Medical, Inc. Drops by -15.77% | Insider Trading Report - Insider Trading Report |
|
|
|
Rockwell Medical, Inc. (NASDAQ:RMTI) has lost 15.77% during the past week and dropped 6.18% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 13.87%. Rockwell Medical, Inc. (NASDAQ:RMTI) has underperformed the index by 5.2% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
For the current week, the company shares have a recommendation consensus of Buy. Rockwell Medical, Inc. is up 46.29% in the last 3-month period. Year-to-Date the stock performance stands at 47.57%. The company shares have rallied 48.29% in the past 52 Weeks. On July 17, 2015 The shares registered one year high of $18.9 and one year low was seen on December 15, 2014 at $8.1. The 50-day moving average is $15.57 and the 200 day moving average is recorded at $11.83. S&P 500 has rallied 5.09% during the last 52-weeks. Rockwell Medical, Inc. (NASDAQ:RMTI) witnessed a decline in the market cap on Friday as its shares dropped 5.13% or 0.82 points. After the session commenced at $15.9, the stock reached the higher end at $15.91 while it hit a low of $15.12. With the volume soaring to 1,315,256 shares, the last trade was called at $15.17. The company has a 52-week high of $18.8999. The company has a market cap of $761 million and there are 50,169,000 shares in outstanding. The 52-week low of the share price is $8.095.
Currently the company Insiders own 5.5% of Rockwell Medical, Inc. Company shares. In the past six months, there is a change of 0% in the total insider ownership. Institutional Investors own 33.9% of Company shares. During last 3 month period, 24.11% of total institutional ownership has changed in the company shares. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
